Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT03797261 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03797261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03797261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
March 18, 2019
Completion date
December 30, 2019
Enrollment
9 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, diffuse large b-cell lymphoma, non-hodgkin's lymphoma